1.Identification of a new azoreductase driven prodrug from bardoxolone methyl and 5-aminosalicylate for the treatment of colitis in mice.
Xin QIAO ; Yan GONG ; Yi MOU ; Yi-Hua ZHANG ; Zhang-Jian HUANG ; Xiao-Dong WEN
Chinese Journal of Natural Medicines (English Ed.) 2021;19(7):545-550
For local treatment of ulcerative colitis, a new azoreductase driven prodrug CDDO-AZO from bardoxolone methyl (CDDO-Me) and 5-aminosalicylate (5-ASA) was designed, synthesized and biologically evaluated. It is proposed that orally administrated CDDO-AZO is stable before reaching the colon, while it can also be triggered by the presence of azoreductase in the colon to fragment into CDDO-Me and 5-ASA, generating potent anti-colitis effects. Superior to olsalazine (OLS, a clinically used drug for ulcerative colitis) and CDDO-Me plus 5-ASA, CDDO-AZO significantly attenuated inflammatory colitis symptoms in DSS-induced chronic colitis mice, which suggested that CDDO-AZO may be a promising anti-ulcerative colitis agent.
Animals
;
Colitis/drug therapy*
;
Mesalamine/pharmacology*
;
Mice
;
Nitroreductases
;
Oleanolic Acid/pharmacology*
;
Prodrugs
2.Chinese Medicine Amygdalin and β-Glucosidase Combined with Antibody Enzymatic Prodrug System As A Feasible Antitumor Therapy.
Yun-Long LI ; Qiao-Xing LI ; Rui-Jiang LIU ; Xiang-Qian SHEN
Chinese journal of integrative medicine 2018;24(3):237-240
Amarogentin is an efficacious Chinese herbal medicine and a component of the bitter apricot kernel. It is commonly used as an expectorant and supplementary anti-cancer drug. β-Glucosidase is an enzyme that hydrolyzes the glycosidic bond between aryl and saccharide groups to release glucose. Upon their interaction, β-glucosidase catalyzes amarogentin to produce considerable amounts of hydrocyanic acid, which inhibits cytochrome C oxidase, the terminal enzyme in the mitochondrial respiration chain, and suspends adenosine triphosphate synthesis, resulting in cell death. Hydrocyanic acid is a cell-cycle-stage-nonspecific agent that kills cancer cells. Thus, β-glucosidase can be coupled with a tumor-specific monoclonal antibody. β-Glucosidase can combine with cancer-cell-surface antigens and specifically convert amarogentin to an active drug that acts on cancer cells and the surrounding antibodies to achieve a killing effect. β-Glucosidase is injected intravenously and recognizes cancer-cell-surface antigens with the help of an antibody. The prodrug amarogentin is infused after β-glucosidase has reached the target position. Coupling of cell membrane peptides with β-glucosidase allows the enzyme to penetrate capillary endothelial cells and clear extracellular deep solid tumors to kill the cells therein. The Chinese medicine amarogentin and β-glucosidase will become an important treatment for various tumors when an appropriate monoclonal antibody is developed.
Amygdalin
;
therapeutic use
;
Antibodies, Monoclonal
;
therapeutic use
;
Antineoplastic Agents
;
therapeutic use
;
Cell-Penetrating Peptides
;
therapeutic use
;
Humans
;
Iridoids
;
therapeutic use
;
Prodrugs
;
therapeutic use
;
beta-Glucosidase
;
therapeutic use
3.Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis.
Guosong SHEN ; Pingya HE ; Yingying MAO ; Peipei LI ; Frank LUH ; Guohui DING ; Xiyong LIU ; Yun YEN
Journal of Breast Cancer 2017;20(2):132-141
PURPOSE: Uridine-cytidine kinase (UCK) 2 is a rate-limiting enzyme involved in the salvage pathway of pyrimidine-nucleotide biosynthesis. Recent studies have shown that UCK2 is overexpressed in many types of cancer and may play a crucial role in activating antitumor prodrugs in human cancer cells. In the current study, we evaluated the potential prognostic value of UCK2 in breast cancer. METHODS: We searched public databases to explore associations between UCK2 gene expression and clinical parameters in patients with breast cancer. Gene set enrichment analysis (GSEA) was performed to identify biological pathways associated with UCK2 gene expression levels. Survival analyses were performed using 10 independent large-scale breast cancer microarray datasets. RESULTS: We found that UCK2 mRNA expression was elevated in breast cancer tissue compared with adjacent nontumorous tissue or breast tissue from healthy controls. High UCK2 levels were correlated with estrogen receptor negativity (p<0.001), advanced tumor grade (p<0.001), and poor tumor differentiation (p<0.001). GSEA revealed that UCK2-high breast cancers were enriched for gene sets associated with metastasis, progenitor-like phenotypes, and poor prognosis. Multivariable Cox proportional hazards regression analyses of microarray datasets verified that high UCK2 gene expression was associated with poor overall survival in a dose-response manner. The prognostic power of UCK2 was superior to that of TNM staging and comparable to that of multiple gene signatures. CONCLUSION: These findings suggest that UCK2 may be a promising prognostic biomarker for patients with breast cancer.
Biomarkers
;
Breast Neoplasms*
;
Breast*
;
Dataset
;
Estrogens
;
Gene Expression
;
Humans
;
Neoplasm Metastasis
;
Neoplasm Staging
;
Phenotype
;
Prodrugs
;
Prognosis*
;
RNA, Messenger
;
Uridine Kinase*
4.A lipophilic prodrug of Danshensu: preparation, characterization, and in vitro and in vivo evaluation.
Xue-Jiao GUO ; Xue-Jiao FAN ; Bin QIAO ; Zhi-Qiang GE
Chinese Journal of Natural Medicines (English Ed.) 2017;15(5):355-362
Danshensu [3-(3, 4-dihydroxyphenyl) lactic acid, DSS], one of the significant cardioprotective components, is extracted from the root of Salvia miltiorrhiza. In the present study, an ester prodrug of Danshensu (DSS), palmitoyl Danshensu (PDSS), was synthesized with the aim to improve its oral bioavailability and prolong its half-life. The in vitro experiments were carried out to evaluate the physicochemical properties and stability of PDSS. Although the solubility of PDSS in water was only 0.055 mg·mL, its solubility in FaSSIF and FeSSIF reached 4.68 and 9.08 mg·mL, respectively. Octanol-water partition coefficient (log P) was increased from -2.48 of DSS to 1.90 of PDSS. PDSS was relatively stable in the aqueous solution in pH range from 5.6 to 7.4. Furthermore, the pharmacokinetics in rats was evaluated after oral administration of PDSS and DSS. AUC and t of PDSS were enhanced up to 9.8-fold and 2.2-fold, respectively, compared to that of DSS. C was 1.67 ± 0.11 μg·mL for PDSS and 0.81 ± 0.06 μg·mL for DSS. Thus, these results demonstrated that PDSS had much higher oral bioavailability and longer circulation time than its parent drug.
Animals
;
Biological Availability
;
Drug Compounding
;
methods
;
Drug Evaluation, Preclinical
;
Hydrogen-Ion Concentration
;
Lactates
;
chemistry
;
pharmacokinetics
;
Male
;
Prodrugs
;
chemistry
;
pharmacokinetics
;
Rats
;
Rats, Sprague-Dawley
;
Salvia miltiorrhiza
;
chemistry
;
Solubility
5.Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Christopher P GUISE ; Alexandra M MOWDAY ; Amir ASHOORZADEH ; Ran YUAN ; Wan-Hua LIN ; Dong-Hai WU ; Jeff B SMAILL ; Adam V PATTERSON ; Ke DING
Chinese Journal of Cancer 2014;33(2):80-86
Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs. Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy. To date, five distinct classes of bioreactive prodrugs have been developed to target hypoxic cells in solid tumors. These hypoxia-activated prodrugs, including nitro compounds, N-oxides, quinones, and metal complexes, generally share a common mechanism of activation whereby they are reduced by intracellular oxidoreductases in an oxygen-sensitive manner to form cytotoxins. Several examples including PR-104, TH-302, and EO9 are currently undergoing phase II and phase III clinical evaluation. In this review, we discuss the nature of tumor hypoxia as a therapeutic target, focusing on the development of bioreductive prodrugs. We also describe the current knowledge of how each prodrug class is activated and detail the clinical progress of leading examples.
Anthraquinones
;
chemistry
;
pharmacology
;
Antineoplastic Agents
;
chemistry
;
pharmacology
;
Aziridines
;
chemistry
;
pharmacology
;
Cell Hypoxia
;
drug effects
;
Humans
;
Indolequinones
;
chemistry
;
pharmacology
;
Molecular Structure
;
NAD(P)H Dehydrogenase (Quinone)
;
chemistry
;
pharmacology
;
Neoplasms
;
drug therapy
;
pathology
;
Nitrogen Mustard Compounds
;
chemistry
;
pharmacology
;
Nitroimidazoles
;
chemistry
;
pharmacology
;
Phosphoramide Mustards
;
chemistry
;
pharmacology
;
Prodrugs
;
chemistry
;
pharmacology
;
Triazines
;
chemistry
;
pharmacology
6.A review of the expression and activity of drug metabolism enzymes in tumorous cells.
Wen-jing XIAO ; Guang-ji WANG ; Ji-ye A
Acta Pharmaceutica Sinica 2014;49(10):1377-1386
Tumorous cells are characterized by distinctive metabolic reprogramming and living conditions. Understanding drug metabolizing features in tumor cells will not only favor the estimation of metabolic rate, elimination half life and the assessment of potency, but also facilitate the optimal design of anti-tumor drugs/prodrugs. This article reviewed the expression and activity features of major drug metabolizing enzymes (DMEs) in solid tumorous tissues, such as liver, intestine, breast and lung, and the difference from the correspondingly normal tissues, exemplified by the metabolic properties of some classic antitumor-agents in tumorous tissues. In combination with the data retrieved in vitro tumor cell lines, we discussed the similarities and differences of DMEs expression and function between tumor tissues (in vivo) and tumor cells (in vitro), and proposed the possible factors that cause the differences.
Antineoplastic Agents
;
pharmacokinetics
;
Cell Line, Tumor
;
Humans
;
Inactivation, Metabolic
;
Liver
;
metabolism
;
Neoplasms
;
enzymology
;
Prodrugs
;
pharmacokinetics
7.Lead compound optimization strategy (3)--Structure modification strategies for improving water solubility.
Zeng LI ; Jiang WANG ; Yu ZHOU ; Hong LIU
Acta Pharmaceutica Sinica 2014;49(9):1238-1247
Water solubility is an essential physical chemistry property of organic small molecule drug and is also a very important issue in drug discovery. Good water solubility often leads to a good drug potency and pleasant pharmacokinetic profiles. To improve water solubility, structure modification is a straight and effective way based on the theory of water solubility. This review summarized valid structure modification strategies for improving water solubility including salt formation, polar group introduction, liposolubility reduction, conformation optimization and prodrug.
Drug Design
;
Prodrugs
;
chemistry
;
Solubility
;
Structure-Activity Relationship
;
Water
;
chemistry
8.Application of phosphates and phosphonates prodrugs in drug research and development.
Xun JI ; Jiang WANG ; Lei ZHANG ; Lin-Xiang ZHAO ; Hua-Liang JIANG ; Hong LIU
Acta Pharmaceutica Sinica 2013;48(5):621-634
Based on the character of the molecular structure, the prodrugs of phosphates and phosphonates were divided into two categories. The first is the drug which contained the phosphate group, introducing protected groups to increase lipophilicity and improve bioavailability. The other one is the drug which had no phosphate group, introducing the phosphate group into molecules to enhance the solubility, regulate the distribution coefficient and enhance the drug-like property. This review focuses on the application of phosphates and phosphonates in drug research and development based on improvement of physico-chemical property, drug safety and the pharmacokinetics.
Animals
;
Biological Availability
;
Drug Design
;
Drug Stability
;
Humans
;
Molecular Structure
;
Organophosphonates
;
chemical synthesis
;
chemistry
;
pharmacokinetics
;
Phosphates
;
chemical synthesis
;
chemistry
;
pharmacokinetics
;
Prodrugs
;
chemical synthesis
;
chemistry
;
classification
;
pharmacokinetics
;
Solubility
;
Structure-Activity Relationship
;
Tissue Distribution
9.The advance in synthetic biology: towards a microbe-derived paclitaxel intermediates.
Wei WANG ; Yan YANG ; Xiao-Dong ZHENG ; Shu-Qiong HUANG ; Lei GUO ; Jian-Qiang KONG ; Ke-Di CHENG
Acta Pharmaceutica Sinica 2013;48(2):187-192
The synthetic biology matures to promote the heterologous biosynthesis of the well-known drug paclitaxel that is one of the most important and active chemotherapeutic agents for the first-line clinical treatment of cancer. This review focuses on the construction and regulation of the biosynthetic pathway of paclitaxel intermediates in both Escherichia coli and Saccharomyces cerevisiae. In particular, the review also features the early efforts to design and overproduce taxadiene and the bottleneck of scale fermentation for producing the intermediates.
Alkenes
;
chemistry
;
metabolism
;
Antineoplastic Agents, Phytogenic
;
biosynthesis
;
chemistry
;
metabolism
;
Biosynthetic Pathways
;
Diterpenes
;
chemistry
;
metabolism
;
Escherichia coli
;
metabolism
;
Fermentation
;
Metabolic Engineering
;
Paclitaxel
;
biosynthesis
;
chemistry
;
metabolism
;
Prodrugs
;
Saccharomyces cerevisiae
;
metabolism
;
Synthetic Biology
10.Biocatalytic desymmetric hydrolysis of 3-(4-chlorophenyl)-glutaronitrile to the key precursor of optically pure baclofen.
Meizhen XU ; Jie REN ; Jingsong GONG ; Wenyue DONG ; Qiaqing WU ; Zhenghong XU ; Dunming ZHU
Chinese Journal of Biotechnology 2013;29(1):31-40
We produced (S)-4-cyano-3-(4-chlorophenyl)-butyrate by highly stereoselective biocatalyst in this study. A nitrilase-producing strain, named Gibberella intermedia WX12, was isolated by 3-(4-chlorophenyl)-glutaronitrile as substrate in the screening with phenol-sodium hypochlorite method. The fermentation conditions and catalytic properties of this strain were investigated. The preferred carbon and nitrogen sources for nitrilase production were lactose (30 g/L) and peptone (20 g/L). After being cultivated for 96 h, the cells were collected for use in biotransformation. The hydrolysis of 3-(4-chlorophenyl)-glutaronitrile was performed at 30 degrees C in phosphate buffer (pH 8.0, 50 mmol/L) for 24 h to give (S)-4-cyano-3-(4-chlorophenyl)-butyric acid with 90% yield and > 99% of ee, which can be used for the synthesis of (R)- and (S)-baclofen. The configuration of product was determined by chemically converting it to baclofen and comparison with the authentic sample by chiral HPLC analysis.
Aminohydrolases
;
metabolism
;
Baclofen
;
chemical synthesis
;
chemistry
;
Biocatalysis
;
Chlorophenols
;
chemistry
;
Gibberella
;
enzymology
;
Hydrolysis
;
Nitriles
;
chemistry
;
Prodrugs
;
chemical synthesis
;
chemistry

Result Analysis
Print
Save
E-mail